AI-generated analysis. Always verify with the original filing.
Lexeo Therapeutics released Q4 and full year 2025 financial results and key pipeline updates for its lead gene therapy candidates on March 30, 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or oth
Other Events. On March 30, 2026, the Company posted on its website an updated corporate presentation (the “ Corporate Presentation ”). The Corporate Presentatio
Financial Statements and Exhibits. (d) Exhibits Col2: Exhibit Description | Col4: Form | Col6: File No. | Col8: Exhibit | Col10: Filing Date Exhibit Number: 99.
| Metric | Value | Basis |
|---|---|---|
| Research and Development Expenses (Q4 2025) | $16.20 | GAAP |
| Research and Development Expenses (Full Year 2025) | $63.80 | GAAP |
| General and Administrative Expenses (Q4 2025) | $6.90 | GAAP |
| General and Administrative Expenses (Full Year 2025) | $45.50 | GAAP |
| Net Loss (Q4 2025) | $20.90 | GAAP |
| Basic and Diluted EPS (Q4 2025) | $-0.27 | GAAP |
| Net Loss (Full Year 2025) | $100.00 | GAAP |
| Basic and Diluted EPS (Full Year 2025) | $-1.86 | GAAP |
Narinder Bhalla, MD
Effective: Not Disclosed
Strengthen cardiac clinical development and commercial expertise
Material Agreement